Biohaven Pharmaceutical Holding Company Ltd.
BHVN
BHVN was delisted on the 3rd of October, 2022.
188 hedge funds and large institutions have $2.67B invested in Biohaven Pharmaceutical Holding Company Ltd. in 2019 Q4 according to their latest regulatory filings, with 34 funds opening new positions, 63 increasing their positions, 69 reducing their positions, and 23 closing their positions.
348% more call options, than puts
Call options by funds: $216M | Put options by funds: $48.3M
48% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 23
31% more capital invested
Capital invested by funds: $2.04B → $2.67B (+$628M)
2% more funds holding
Funds holding: 184 → 188 (+4)
9% less repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 69
14% less funds holding in top 10
Funds holding in top 10: 14 → 12 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
+$74.7M |
| 2 |
Capital World Investors
Los Angeles,
California
|
+$58.3M |
| 3 |
PC
Polar Capital
London,
United Kingdom
|
+$24.8M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$22.5M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$19.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$33.4M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$33.2M |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
-$19.9M |
| 4 |
TAL
TIG Advisors LLC
New York
|
-$19.2M |
| 5 |
Brown Advisory
Baltimore,
Maryland
|
-$18.9M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ARTA
201
A.R.T. Advisors
New York
| – | -$423K | -10,142 | Closed |
|
|
BFM
202
Boothbay Fund Management
New York
| – | -$502K | -10,142 | Closed |
|
|
VF
203
Virtu Financial
New York
| – | -$268K | -6,419 | Closed |
|
|
TRCT
204
Tower Research Capital (TRC)
New York
| – | -$83.1K | -1,678 | -100% |
|
205
Victory Capital Management
San Antonio,
Texas
| – | -$51K | -1,215 | Closed |
|
|
QT
206
Quantbot Technologies
New York
| – | -$18K | -450 | Closed |
|
|
IUHSA
207
Itau Unibanco Holding S.A.
Sao Paulo,
Brazil
| – | -$15K | -336 | Closed |
|
208
Walleye Capital
New York
| – | -$8K | -200 | Closed |
|
209
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| – | -$4K | -86 | Closed |
|
|
GWS
210
Glassman Wealth Services
Vienna,
Virginia
| – | +$50 | +1 | New |
|
BHVN Hedge Fund Activity: Q4 2019 in Review
188 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Biohaven Pharmaceutical Holding Company Ltd. (BHVN) for Q4 2019, worth a combined $2.67B — up 31% from $2.04B a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new BHVN positions and 23 closed out — a net gain of 11 holders — while 63 added to existing stakes and 69 trimmed.
The largest buyer was Capital International Investors, adding an estimated $74.7M. The largest seller was Adage Capital Partners, cutting an estimated $33.4M.
- 188 institutional investors held Biohaven Pharmaceutical Holding Company Ltd. (BHVN) as of Q4 2019, up from 184 in Q3 2019.
- Funds reported $2.67B of Biohaven Pharmaceutical Holding Company Ltd. stock for Q4 2019, up 31% quarter-over-quarter.
- 34 funds opened new Biohaven Pharmaceutical Holding Company Ltd. positions in Q4 2019 and 23 closed out, a net change of +11 holders.
- The largest Biohaven Pharmaceutical Holding Company Ltd. buyer in Q4 2019 was Capital International Investors, an estimated $74.7M added.
- The largest Biohaven Pharmaceutical Holding Company Ltd. seller in Q4 2019 was Adage Capital Partners, an estimated $33.4M sold.
Based on aggregated 13F filings for Q4 2019.